#natera

  1. Breaking Down Natera: 10 Analysts Share Their Views

    By Benzinga Insights Natera (NASDAQ: NTRA ) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the pa
  2. Cracking The Code: Understanding Analyst Reviews For Natera

    By Benzinga Insights During the last three months, 9 analysts shared their evaluations of Natera (NASDAQ: NTRA ), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 d
  3. The Analyst Landscape: 8 Takes On Natera

    By Benzinga Insights During the last three months, 8 analysts shared their evaluations of Natera (NASDAQ: NTRA ), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 d
  4. Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday

    By Lisa Levin U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session. Virgin Galactic Holdings, Inc. (NYSE: SPCE ) shares jumped 27.5% to $1.99 after the company reported better-than-expec
  5. Natera wins $19 million US verdict from ArcherDX in cancer-detection patent case

    By: Blake Brittain (Reuters) - Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for infringing patents related to cancer detection. The jury agreed with Natera that biotech company Arche